Cu-diacetyl-bis (N4-methylthiosemicarbazone) (CuATSM) has both anti-oxidative and anti-inflammatory activities, but its therapeutic efficacy for oxidative stress has not been thoroughly investigated in acute ischemic stroke. Here, the present study was designed to assess the efficacies of CuATSM in acute ischemic stroke by comparing with the standard neuroprotective reagent edaravone. Mice were subjected to transient middle cerebral occlusion (tMCAO) for 60 min, and then intravenously administrated with CuATSM (1.5 mg/kg) or edaravone (3 mg/kg) just after the reperfusion, and examined at 1 and 3 d. Compared with the vehicle group, CuATSM treatment decreased infarct volumes and oxidative stress at 3d after tMCAO, which was further enhanced by combined CuATSM + edaravone treatment as compared with single CuATSM group, but not improve neurobehaviors. The present study demonstrated that CuATSM showed strong antioxidative and neuroprotective effects in acute ischemic stroke, which was enhanced by the combination with edaravone.

中文翻译：

---

CuATSM通过改善氧化应激对小鼠卒中模型的神经保护作用

Cu-二乙酰-双（N4-甲基氨基硫脲）（CuATSM）具有抗氧化和抗炎活性，但其对氧化应激的治疗功效尚未在急性缺血性中风中得到彻底研究。在这里，本研究旨在通过与标准神经保护试剂依达拉奉进行比较来评估 CuATSM 在急性缺血性中风中的疗效。小鼠进行短暂性大脑中段闭塞（tMCAO）60 min，再灌注后立即静脉注射CuATSM（1.5 mg/kg）或依达拉奉（3 mg/kg），并在第1天和第3天进行检查。与载体组相比，CuATSM 治疗在 tMCAO 后 3 d 减少了梗塞体积和氧化应激，与单一 CuATSM 组相比，CuATSM + 依达拉奉联合治疗进一步增强，但没有改善神经行为。